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Abstract
Chronic heart failure is a debilitating condition with a poor prognosis despite advances in
medical and invasive treatment modalities. Attempts have been made to improve risk stratifi-
cation in order to single out very-high-risk patients who could benefit from invasive and costly
therapies. Unfortunately clinical, echocardiographic, radiological or biochemical measure-
ments performed at rest provide significant diagnostic information but fail to stratify the risk
sufficiently. Cardiopulmonary exercise testing alone or in combination with stress
echocardiography and biomarkers may offer a more profound insight into the progress of the
disease and patient prognosis and aid in the choice of the most appropriate therapy. Peak
oxygen consumption (pVO2) is the most powerful prognostic parameter obtained during cardi-
opulmonary exercise testing. Ventilation slopes, especially the slope of ventilation to CO2 pro-
duction (VE/VCO2), can have additional prognostic value or be used as a surrogate risk
predictor where exercise is sub-maximal. Other cardiopulmonary parameters seem to have, at
best, an auxiliary role in risk assessment. In patients with grey zone pVO2 values the presence
of contractile reserve on stress or dobutamine echocardiography can be prognostically favour-
able. Other echocardiographic findings, such as functional mitral regurgitation, pulmonary
hypertension and right ventricle dysfunction, also yield prognostic information. Combining
biomarker measurements with pVO2 obtained during the cardiopulmonary exercise test may
further improve risk assessment in heart failure patients. Two markers, B type natriuretic
peptides and high sensitivity C-reactive protein (hsCRP), both with established prognostic
value in heart failure and cardiovascular diseases in general, are the best candidates for
combined assessment with cardiopulmonary test results. Further studies are needed to confirm
this notion. (Cardiol J 2007; 14: 340–346)
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Introduction
In spite of advances in the therapy of chron-
ic heart failure, the prognosis with regard to this
disease remains dismal. Routine clinical, echocar-
diographic and radiological examinations performed
at rest suffice for the right diagnosis but have limit-
ed prognostic value. This may result from the com-
plexity of the pathophysiological mechanisms
involved in heart failure and the fact that heart dysfunc-
tion leads to multiple circulatory and extracirculatory
consequences. These include compromised periph-
eral circulation, skeletal muscle hypoperfusion and
abnormal pulmonary ventilation. Hypoperfusion of
the skeletal muscles is a result of peripheral vaso-
constriction, which leads to muscular atrophy and
increases the number of glycolic fibres at the ex-
pense of oxygen-dependent myocytes. Pulmonary
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congestion results in increased dead space and re-
duced vital capacity or even bronchial obstruction
due to overload of the bronchial veins. These proc-
esses are mediated by hemodynamic, humoral and
inflammatory mechanisms. Their intensity reflects
the stage of heart failure and influences the prog-
nosis. This is a pathophysiological basis for the use
of stress tests, especially cardiopulmonary exercise
testing, aided by stress echocardiography in some
cases, in determining the prognosis in patients with
heart failure.
Cardiopulmonary exercise testing enables
a complex and objective evaluation to be made of
physical capacity and the factors influencing it, such
as ventilatory and circulatory capacity and muscu-
lar endurance, all of which reflect the severity (thus
the stage) of heart failure and determine the prog-
nosis [1]. In the event of an equivocal cardiopulmo-
nary exercise test result further prognostic infor-
mation can be derived from stress echocardiogra-
phy or biomarker levels, especially concentration
of B-type natriuretic peptides (BNP). All these
prognostic factors taken together may improve
prognostication in heart failure and contribute to its
more effective therapy.
Peak oxygen consumption
The basic and most widely measured parame-
ter during cardiopulmonary exercise testing is peak
oxygen consumption (pVO2), which reflects the
peak aerobic capacity of the patient. pVO2 correlates
weakly with hemodynamic measurements per-
formed at rest but relates much better to maximum
cardiac output determined during stress tests [2].
pVO2 is a measure of cardiovascular functional re-
serve in patients with heart dysfunction, as was
demonstrated for the first time by Weber et al. [3]
over 20 years ago. Several years later it was report-
ed for the first time that pVO2 has a prognostic val-
ue in patients with heart failure. The study includ-
ed 27 heart failure patients. pVO2 < 10 ml/
/kg/min translated into a 77% annual death rate,
whereas pVO2 10–18 ml/kg/min meant a significantly
lower 22% risk of death in one year [4]. Further stud-
ies confirmed the ability of pVO2 to predict overall
mortality [5]. pVO2 remained a statistically significant
predictor, even when other variables with strong
independent prognostic power such as age, natriuretic
peptide levels and left ventricle systolic function were
included [6]. This strongly supports the independent
prognostic value of pVO2 in heart failure.
A parameter with prognostic value which does
not influence therapeutic decisions is of limited
clinical use. pVO2 seem to be able to provide clinical-
ly useful information beyond pure prognostication
in patients with heart failure. This was demonstrat-
ed in a pivotal study by Mancini et al. [7]. Of pa-
tients qualified for heart transplantation (n = 116)
pVO2 < 14 ml/kg/min identified individuals who
would benefit from this procedure, while values above
14 ml/kg/min implied that transplantation could
safely be deferred. In the latter group annual sur-
vival rate was 94% (n = 52), whereas among pa-
tients with pVO2 < 14 ml/kg/min who were not
qualified for transplantation because of co-morbid-
ities the annual survival rate was only 47% (n = 27).
On the other hand in patients with low preopera-
tive pVO2 (< 14 ml/kg/min) who subsequently un-
derwent heart transplantation the annual survival
rate was 83% (n = 24). In short, the one-year sur-
vival prognosis was comparable in patients with
pVO2 > 14 ml/kg/min treated conservatively and in
patients with pVO2 < 14 ml/kg/min subjected to
heart transplantation and significantly better than
in patients with pVO2 < 14 ml/kg/min treated con-
servatively. The results of Mancini et al. [7] result-
ed in the inclusion of pVO2 and cardiopulmonary
exercise testing in routine patient evaluation pre-
ceding heart transplantation.
As shown above, in heart failure patients with
a very poor prognosis pVO2 does not reach 10 ml/
/kg/min. On the other hand patients with a very good
prognosis achieve pVO2 > 18 ml/kg/min. Thus there
remains a grey zone of pVO2 values between 10 and
18 ml/kg/min, which can further be stratified into
two ranges: the first, of 10–14 ml/kg/min, is char-
acteristic of patients with a poor prognosis, and the
other, at 14–18 ml/kg/min, is typical of patients with
a moderate prognosis [8]. These ranges are not very
different from the pVO2 cut-offs recommended for
heart failure staging according to Weber et al. [3]
(Table 1). The question which arises is whether pa-
tients with intermediate pVO2 values can be more
accurately assessed in terms of prognosis and pos-
sible optimisation of therapy. Another important
issue is risk assessment in patients who cannot
perform maximum effort for reasons other than
exhaustion of cardiovascular capacity. To answer
these questions researchers have so far carried out
numerous studies which have evaluated the prog-
nostic value of parameters other than pVO2.
Other cardiopulmonary parameters
Percentage maximum predicted oxygen con-
sumption (%VO2 max) is, in theory, superior to
pVO2, because it is a measure of achieved aerobic
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capacity adjusted for sex, age and body mass. Of two
well documented studies comparing the prognos-
tic value of both parameters neither is fully conclu-
sive as to the superiority of one or the other. One
showed the prognostic equivalence of pVO2 and
%VO2 max in patients with heart failure [9], where-
as in the other %VO2 max predicted mortality bet-
ter than the absolute value of pVO2 [10]. In this study
%VO2 max < 50% was related to a significantly
poorer prognosis. In another study, which included
500 patients with heart failure, three-year survival
was comparable in groups with pVO2 < 14, and pVO2 >
> 14 ml/kg/min indicated that the decreased pVO2
in the former group exceeded 50% of %VO2 max [11].
The task of proving the superiority of either param-
eter can thus be difficult. It cannot be ruled out that
%VO2 max has a greater prognostic value in patients
at the extremes of age and in women. This question
cannot be answered unequivocally at present.
Some authors postulate that pVO2 should be
expressed in ml/kg/min, with adjustment for lean
body mass calculated on the basis of fatty tissue
layer measured in a standard place. Such an ap-
proach can be justified in cases of obesity, since fatty
tissue is metabolically inert and constitutes a signif-
icant portion of body weight in the obese. It has been
shown that pVO2 = 19 ml/kg (lean body mass)/min
is a more powerful prognosticator that pVO2 =
= 14 ml/kg (total body weight)/min [12].
Use of the anaerobic threshold (AT), which is
oxygen consumption measured at the moment of
anaerobic metabolism onset, is an interesting con-
cept, because it decreases along with pVO2 in heart
failure. In theory AT should be a good surrogate for
pVO2 where there is sub-maximal effort limited by
factors other than exhaustion of cardiovascular
reserve and including lack of patient motivation. Un-
fortunately AT is in no way prognostically superior
to pVO2. Moreover its precise determination re-
quires invasive procedures (arterial line) and non-
invasive methods may yield inaccurate results [13].
Another cardiopulmonary parameter of poten-
tial prognostic value in heart failure is the slope of
the curve of ventilation to carbon dioxide produc-
tion (VE/VCO2) expressed as a regression coeffi-
cient of this curve. Excess of minute ventilation in
relation to CO2 production is characteristic of pa-
tients with heart failure and causes the VE/VCO2
slope to run more steeply (VE/VCO2 > 32–35). This
phenomenon is called an “enhanced ventilatory re-
sponse” (EVR). Its degree appears to correspond
to the severity of heart failure. The prognostic val-
ue of the VE/VCO2 slope has been evaluated in sev-
eral studies. In a well designed and conducted study
Chua et al. [14] showed that, in 173 patients with
heart failure, EVR defined as a VE/VCO2 slope >
> 34 produced a worse prognosis. In fact 18-month
survival in patients without EVR was 95% and only
69% in patients presenting this abnormality
(p = 0.0001). Furthermore in a multivariate analy-
sis the VE/VCO2 slope was an independent prog-
nostic factor which contributed additional predictive
information to that obtained from pVO2. In the study
by Pardaens et al. [15] ventilatory slopes including
VE/VCO2 (after logarithmic transformation) did not
add any prognostic information beyond that provid-
ed by pVO2. Ventilation slopes acquired prognostic
value only after pVO2 was eliminated from multi-
variate analysis, whereas pVO2 retained its ability
to predict cardiovascular events and death regard-
less of the presence of ventilatory data in the anal-
ysis. In this study ventilation slopes were deter-
mined for sub-maximal effort where the respirato-
ry exchange ratio (RER) was below or equalled
1.0 (RER £ 1.0). On the other hand Chua et al. [14]
determined the VE/VCO2 slope for maximal effort.
Thus one can assume that the VE/VCO2 slope re-
tains its full prognostic value additive to that offered
by pVO2 in the case of maximal effort and should be
treated as a surrogate prognostic parameter in sub-
maximal efforts (with RER £ 1.0). More recent
studies confirm the role of ventilation slopes in risk
Table 1. Heart failure staging based on pVO2 according to Weber and Janicki compared with pVO2
ranges recommended for prognostic purposes.
Heart failure pVO2 ranges according to Prognosis pVO2 ranges according to
stage Weber et al. [ml/kg/min] Lainchbury and Richards [ml/kg/min]
A > 20 Good > 18
B 16–20 Moderate 14–18
C 10–16 Poor 10–14*
D 6–10 Very poor < 10*
E < 6
*Heart transplantation should be considered [7]
343
Wiktor Piechota and Grzegorz Gielerak, The prognostic value of stress tests in chronic heart failure
www.cardiologyjournal.org
assessment in heart failure patients [16]. Other
cardiopulmonary parameters were also evaluated.
These include an oxygen pulse which is a ratio of
VO2 and a heart rate dependent on stroke volume
and arteriovenous oxygen concentration difference.
A flat oxygen pulse curve during exercise implies
a lack of inotropic reserve, leading to an inadequate
increase in myocardial contractility at exertion.
Such a pattern is typically observed in heart failure
with severe left ventricle dysfunction or in multi-
vessel coronary artery disease, where exertion may
cause extensive myocardial stunning. Unfortunately
in a study by Cohen-Solal et al. [17] oxygen pulse
had no prognostic value. Moreover its mean values
were the same in a group of patients whether they
survived or died during follow up. In a subsequent
study by the same main investigator the product of
oxygen pulse and systolic blood pressure (SBP) did
not have any prognostic value either, as opposed to
the product of VO2 and SBP (referred to as circula-
tory or cardiac power), which turned out to be an in-
dependent predictor in multivariate analysis [18].
Failure to find cardiopulmonary parameters
equivalent to or better than pVO2 in determining
a prognosis has resulted in attempts to combine
pVO2 with other parameters that can be obtained
during any type of exercise stress, for example
maximum mean or maximum SBP and exercise du-
ration. The product of maximum SBP and pVO2
(peak circulatory power) turned out to have prog-
nostic value in the previously quoted study by Co-
hen-Solal et al. [17]. In another study, which has also
been already quoted, with 500 heart failure patients
followed up for three years, the authors analysed
maximum heart rate, maximum SBP, RER, minute
ventilation and AT in addition to standard pVO2
expressed as %VO2 max. Of all these parameters
only %VO2 max and maximum systolic blood pres-
sure showed independent prognostic value. Three-
year survival was 55% in the group with maximum
SBP < 120 mm Hg and 83% with SBP > 120 mm Hg
(p = 0.004) [11]. It should be of no surprise that
a larger inotropic reserve of the heart and its abili-
ty to generate higher blood pressure is associated
with a better prognosis. This has also been con-
firmed by the study of Williams et al. [19], in which
of many parameters with confirmed prognostic val-
ue in univariate analysis, such as pVO2, duration of
exercise, peak circulatory power, maximum systo-
lic and mean blood pressure, NYHA class and
NT-proBNP concentration, only the duration of ex-
ercise and maximum systolic blood pressure inde-
pendently predicted the risk of death in 85 patients
with heart failure. In this study the relative risk of
death was 1.28 (p = 0.007) and 1.27 (p = 0.01) for
a shorter exercise time and lower maximum systo-
lic blood pressure, respectively.
Stress and dobutamine echocardiography
If the issue of prognosis determination on the
basis of sub-maximal effort can be considered at
least partially solved as a result of ventilation slope
analyses, there remains a problem of further and more
detailed risk assessment in the grey zone patients
with moderate and poor prognoses corresponding to
pVO2 values between 10 and 18 ml/kg/min (Table 1).
Thus attempts have been made to stratify risk more
precisely in these groups of patients by using alter-
native stress tests such as dobutamine echocardiog-
raphy. Paraskevaidis et al. [20] showed that in pa-
tients with dilated cardiomyopathy (n = 27) and
intermediate pVO2 (10–14 ml/kg/min) response to
low-dose dobutamine (10 mg/kg/min) had a prognos-
tic value over 18 months of follow up. In patients
who died (n = 19) the authors found a significant
increase in left ventricle end-systolic strain and end-
diastolic dimension. In patients who survived (n = 18)
these parameters did not change during dobutamine
infusion. Other important prognostic parameters
derived from dobutamine or stress echocardiogra-
phy include contractile reserve (ejection fraction
increase), the dynamics of functional mitral regur-
gitation, the presence of pulmonary hypertension
and right ventricle dysfunction [21]. These param-
eters appear to have an additional prognostic value
in heart failure patients with pVO2 between 10 and
14 ml/kg/min (Table 2). More detailed prognostica-
tion on the basis of stress/dobutamine echocardiog-
raphy in the case of intermediate pVO2 is mainly
reserved for dilated cardiomyopathy, although the
presence of a significant contractile reserve in pa-
tients with ischemic heart disease is also predic-
tive of a better prognosis, provided that revascu-
larisation is attempted.
Cardiopulmonary exercise testing
in conjunction with biomarkers
and clinical assessment
Interesting results have been presented by tri-
alists who compared the prognostic value of pVO2
with that of natriuretic peptides, biomarkers whose
role in risk stratification have long been established,
and clinical risk assessment scales, especially the
heart failure survival score (HFSS), which was de-
veloped to predict the necessity of heart transplan-
tation in patients with advanced heart failure [22].
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This scale comprises seven variables which inde-
pendently predicted the risk of death in a multi-
variate model derived from 289 patients and pro-
spectively verified in 199 patients with advanced
heart failure qualified for heart transplantation.
They include the presence of ischemic heart dis-
ease, intraventricular conduction delay (both are
categorical variables), left ventricle ejection fraction,
pVO2, serum natrium concentration, mean blood
pressure and heart rate (continuous variables). In the
study by Gardner et al. [23] with 142 severe heart
failure patients qualified for transplantation a sin-
gle NT-proBNP measurement was more predictive
of death (the primary end-point) and death or ur-
gent transplantation (secondary combined end-
point) than pVO2 and HFSS. During a one-year fol-
low up 16 out of 20 deaths occurred in the group
with NT-proBNP above the median (> 1490 pg/ml)
and only four in the group with NT-proBNP below
this value, which translates into a relative risk of
death of 5.0 in patients with elevated NT-proBNP.
On the other hand de Groote et al. [24] showed that
BNP concentration did not limit the prognostic val-
ue of pVO2 in a group of heart failure patients with
ejection fraction below 45%. In this study the val-
ue of pVO2 (expressed as %VO2 max) in predicting
the risk of death was independent of and additional
to information offered by BNP. In follow up of over
two years the relative risk of death was 3.17 in the
group with BNP over the median. In the same study
aldosterone concentration was also an independent
prognosticator. Inconsistency in the findings by
Gardner et al. [23] and de Groote et al. [24] may be
apparent. In the former trial to compare pVO2 and
NT-proBNP the patients were more severely ill
(they were qualified for heart transplantation) and
were quite homogenous in this respect, with narrow
ranges of values of the potential predictors (EF =
= 14.9 ± 7.1%; pVO2 = 11.8 ± 3.6 ml/kg/min).
At the same time the range of NT-proBNP concen-
trations was, remarkably, 1490 (511–3887) pg/ml
(median and interquartile range). Therefore it
should not be surprising that the ability of NT-proBNP
to stratify the risk was preserved and the prognos-
tic value of other parameters (especially ejection
fraction and pVO2) was lost. In the latter study the
patients’ conditions varied to a greater extent and
most of the participants did not have end-stage
heart failure; the maximum ejection fraction was
45% and BNP median concentration was 109 pg/ml.
The narrower dynamic range of BNP compared to
NT-proBNP could also account for the difference
observed between the two studies.
An interesting combination of cardiopulmonary
exercise testing and biomarker measurement was
proposed by Lainchbury et al. [25]. This team per-
formed an cardiopulmonary exercise test on
68 heart failure patients in NYHA classes III/IV,
measuring BNP before the test and at peak exer-
cise. In multivariate analysis an increase in BNP
during exercise was a good predictor, whereas its
decrease implied a poor prognosis; two-year mor-
tality was 15% in the group with a BNP increase
and 45% in the group with a BNP decrease during
exercise (p < 0.01).
In a study by French investigators BNP and
high-sensitivity C-reactive protein (hsCRP) were
measured along with pVO2 in 545 patients with heart
failure of mixed etiology (dilated and ischemic car-
diomyopathy) undergoing cardiopulmonary exercise
testing. The patients were followed for 2.5 years (me-
dian time) [6]. In a multivariate analysis concentra-
tions of BNP and hsCRP independently predicted
cardiovascular death. After the usion of pVO2 in the
prognostic model it turned out to be the strongest
predictor of death (RR = 4.30); however both bi-
omarkers retained their independent and additive
predictive value (RR = 1.98 for BNP and RR = 1.55
for hsCRP). It is interesting that hsCRP was a sig-
nificant predictor only in the group of patients with
ischemic cardiomyopathy,and the prognostic cut-off
was 3.0 mg/L, which is identical to the cut-off
Table 2. Prognostic value of stress and dobutamine echocardiography in patients with heart failure and
intermediate pVO2 values (10–14 ml/kg/min).
Low risk (5–10%/year) High risk (> 25–30%/year)
Contractile reserve of the left ventricle Present Absent
Mitral regurgitation Not changing or decreasing  Increasing during
during stress/dobutamine infusion stress/dobutamine infusion
Pulmonary hypertension < 45 mm Hg > 45 mm Hg
Right ventricle dysfunction Absent Present
Exercise duration (during stress ≥ 8 min < 8 min
echocardiography)
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proposed by Ridker [26] for risk stratification in
primary and secondary prevention of coronary artery
disease.
Summary
Stress tests provide additional prognostic in-
formation in patients with heart failure. They help
to improve traditional risk stratification based on
clinical, resting echocardiographic and radiological
assessment. Of the many parameters obtained dur-
ing cardiopulmonary exercise testing pVO2 is still
the most powerful predictor of adverse events, in-
cluding death. pVO2 can be expressed as %VO2 max,
which is potentially better adjusted for age, sex and
body mass. In spite of this the absolute value of
pVO2 of less than 14 ml/kg/min is still considered
a decision cut-off in the process of qualifying pa-
tients for heart transplantation. Possibly heart
transplantation can be safely deferred if %VO2 max
exceeds 50, even in cases of absolute measured
pVO2 below 14 ml/kg/min.
It has to be stressed that for risk stratification
in the general heart failure population, significant-
ly broader than the group of heart transplantation
candidates, pVO2 = 14 ml/kg/min alone has a limit-
ed prognostic value. It appears that there is no sin-
gle threshold pVO2 value corresponding to a par-
ticular risk, but that pVO2 should rather be viewed
as a continuous variable determining the risk in
a gradual fashion. The slope of ventilation to car-
bon dioxide production (VE/VCO2 slope) can have
an additive and independent prognostic value in the
case of maximal effort (RER > 1.0). Where there
is sub-maximal effort (symptom-limited or prema-
turely terminated owing to inadequate patient mo-
tivation), it is acceptable to use the VE/VCO2 slope
as a surrogate prognostic marker. In the risk assess-
ment of heart failure patients undergoing cardio-
pulmonary exercise testing easily obtainable param-
eters such as maximum systolic blood pressure and
exercise duration should also be considered, al-
though their actual prognostic importance remains
to be confirmed in further studies.
Peak oxygen consumption remains the prima-
ry cardiopulmonary parameter determining the risk
of adverse events, mostly death, in heart failure pa-
tients. Other parameters, especially ventilation
slopes can have additional value. This also includes
cases where VO2 is of limited use (effort is sub-
maximal or pVO2 is not reached). In the case of pVO2
in the grey zone, especially in the range of 10–
–14 ml/kg/min, stress or dobutamine echocardiogra-
phy may contribute additional prognostic information.
Attempts at combining biomarker measurement,
especially natriuretic peptides and hsCRP, with car-
diopulmonary exercise testing yield promising re-
sults.
This article does not summarise all the param-
eters that can be of prognostic value in heart fail-
ure patients. The authors’ intention was to discuss
risk assessment methods of proven clinical and
prognostic importance. Available data indicate that
combined assessment of the hemodynamic and neu-
rohormonal responses to exercise allows a better
risk stratification and helps to identify high-risk
patients who will benefit from invasive and costly
therapies and low-risk patients who can safely be
treated medically.
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